CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21
The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids
SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
(1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “Toxicity Testing in the 21st Century: A Vision and a Strategy”, Fontem Ventures B.V. have investigated the utility of a series of...